VOLUNTARY ANNOUNCEMENT: DRUG REGISTRATION CERTIFICATE FOR BIMATOPROST EYE DROPS WAS ISSUED

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

China Grand Pharmaceutical and Healthcare Holdings Limited

遠大醫藥健康控股有限公司*

(Incorporated in Bermuda with limited liability)

(Stock Code: 00512)

VOLUNTARY ANNOUNCEMENT

DRUG REGISTRATION CERTIFICATE FOR BIMATOPROST EYE DROPS

WAS ISSUED

This announcement is made by the board of directors (the "Board") of China Grand Pharmaceutical and Healthcare Holdings Limited (the "Company", together with its subsidiaries, the "Group") on a voluntary basis.

The Board is pleased to announce that "Bimatoprost Eye Drops" (specification: 9mg), an innovative ophthalmic solution independently developed by the Group, has been issued a drug registration certificate by the National Medical Products Administration of the People's Republic of China, which is the first approved generic drug in China for this variety.

Bimatoprost eye drops are used to lower the intraocular pressure of patients with primary open-angle glaucoma ("POAG") and ocular hypertension. It is currently the first choice of drugs in the market for the treatment of POAG and ocular hypertension. According to the information obtained from Meta-analysis method, it shows that compared among prostaglandin analogs (PGA) products which is the first-line therapy commonly used in the treatment of POAG, bimatoprost has exhibited better effectiveness in lowering intraocular pressure then other products. International glaucoma treatment guidelines in places such as China, Europe, the United States, and Asia Pacific recommend that bimatoprost eye drops is the first choice for POAG monotherapy. In addition, the Group applied for three patents for its bimatoprost eye drops in Mainland China, all of which have been granted.

Glaucoma poses a serious threat to people's vision health and is the second leading cause of blindness in China. According to statistics from Frost & Sullivan, there are nearly 20 million glaucoma patients in China in 2019, of which open-angle glaucoma accounted for approximately 43.1%. It is estimated that by 2030, the number of glaucoma patients will increase to 23 million. Currently, glaucoma is mainly divided into primary open-angle glaucoma and primary angle-closure glaucoma (PACG). Since it may be asymptomatic, POAG is often found incidentally on a comprehensive ocular examination or a relatively late stage when the risk of irreversible vision loss is high. The market potential for the diagnostics and treatment of open-angle glaucoma is tremendous with huge but unmet clinical demands due to the rapid increase in the number of patients and the long-term medication needs of glaucoma patients.

As one of the largest integrated enterprises specializing in the research and development, production and sales of ophthalmic drugs, the Group's existing products cover various ocular surface diseases and ocular fundus diseases, with strong brand awareness. To consolidate andstrengthen the Group's leading position in ophthalmology, the Group has been committed to the development and introduction of innovative products and first generics in this field, which are indicated for a variety of indications with huge but unmet clinical demands such as dry eye disease and pterygium. Meanwhile, the Group is paying efforts to build an ecosystem for eye protection, and to make advancements on the research and development of ophthalmic devices and consumables. The commercialization approval of the new ophthalmic solution bimatoprost eye drops, which was independently developed by the Group, once again proved the Group's R&D capabilities in ophthalmic drugs. At the same time, it further expands the product line in the field of ophthalmology and continuously consolidates the Group's leading position in the industry of ophthalmic drugs.

The Group always puts focus on the R&D of innovative products and advanced technologies. Sticking to patients-centered, the Group will continue to independently develop innovative products and enhance the competitiveness of its products. The Group will further enhance its overall competitive edges, particularly in cost efficiency and technology, and provide patients with high-quality and competitive drug options.

Warning

The production, sales and corresponding profit of aforementioned product is subject to various factors such as market changes with uncertainty. Shareholders and prospective investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board

China Grand Pharmaceutical and

Healthcare Holdings Limited

Liu Chengwei

Chairman

Hong Kong, 3 March 2021

As at the date of this announcement, the Board comprises four executive directors, namely, Mr. Liu Chengwei, Mr. Hu Bo, Dr. Shao Yan and Dr. Niu Zhanqi and three independent non-executive directors, namely, Ms. So Tosi Wan, Winnie, Dr. Pei Geng and Mr. Hu Yebi.

* For identification purpose only